The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances

ConclusionFinerenone emerges as a valuable addition to CKD therapy, demonstrating potential benefits in  delaying CKD progression while minimizing side effects. Nevertheless, further clinical trials are necessary to provide a comprehensive understanding of its safety and efficacy.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research